Antibody-Drug Conjugate (ADC) Research in Ophthalmology-a Review

Shen, Jie; Attar, Mayssa
November 2015
Pharmaceutical Research;Nov2015, Vol. 32 Issue 11, p3572
Academic Journal
Similar to cancer, many ocular proliferative disorders could be treated with a specific antibody conjugated to a toxin. Active targeting to inhibit epithelial and endothelial cell proliferation in the eye has been tested using antibody-drug conjugates (ADC) both pre-clinically and clinically. Achieving efficacious drug concentrations in the eye, in particular to treat back of the eye disorders is challenging, and the promise of targeted antibody mediated delivery holds great potential. In this review, we describe the research efforts in drug targeting using ADC for the treatment of choroidal neovascularization (CNV), posterior lens capsule opacification, and proliferative vitreoretinopathy. Among these disorders, CNV represents a more active research focus, with more target antigens tested, given the disease prevalence and wider target antigen selection based on current understanding of the pathophysiology of the disease. However, the only research advancing to testing in clinical stage is for posterior lens capsule opacification. Compared to oncology, ADC research and development in ophthalmology is much more limited, possibly due to availability of successful therapies that could be administered locally with limited concern of off-target drug toxicity.


Related Articles

  • Ado-trastuzumab Emtansine.  // AHFS Consumer Medication Information;Feb2020, p1 

    Ado-trastuzumab emtansine injection is used to treat a certain type of breast cancer that has spread to other parts of the body and has not improved or has worsened after treatment with other medications. Ado-trastuzumab emtansine is in a class of medications called antibody-drug conjugates. It...

  • Evolving Strategies for Target Selection for Antibody-Drug Conjugates. Damelin, Marc; Zhong, Wenyan; Myers, Jeremy; Sapra, Puja // Pharmaceutical Research;Nov2015, Vol. 32 Issue 11, p3494 

    Antibody-drug conjugates (ADCs) represent a promising modality for the treatment of cancer. The therapeutic strategy is to deliver a potent drug preferentially to the tumor and not normal tissues by attaching the drug to an antibody that recognizes a tumor antigen. The selection of antigen...

  • Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice. Janthur, Wolf-Dieter; Cantoni, Nathan; Mamot, Christoph // International Journal of Molecular Sciences;Dec2012, Vol. 13 Issue 12, p16020 

    Drug conjugates have been studied extensively in preclinical in vitro and in vivo models but to date only a few compounds have progressed to the clinical setting. This situation is now changing with the publication of studies demonstrating a significant impact on clinical practice and...

  • Targeted Cancer Therapy by Immunoconjugated Gold-Gold Sulfide Nanoparticles Using Protein G as a Cofactor. Sun, Xinghua; Zhang, Guandong; Patel, Dhruvinkumar; Stephens, Dennis; Gobin, Andre // Annals of Biomedical Engineering;Oct2012, Vol. 40 Issue 10, p2131 

    Gold-gold sulfide nanoparticles (GGS-NPs) fabricated from chloroauric acid and sodium thiosulfate show unique near infrared (NIR) absorption that renders them as a promising candidate for photothermal cancer therapy. To improve targeting efficiency, we developed a versatile method to allow...

  • Management of Metastatic Breast Cancer with Second-Generation Antibody-Drug Conjugates: Focus on Glembatumumab Vedotin (CDX-011, CR011-vcMMAE). Vaklavas, Christos; Forero, Andres // BioDrugs;Jun2014, Vol. 28 Issue 3, p253 

    Exploiting the highly targeted nature of monoclonal antibodies to deliver selectively to tumor cells a cytotoxic payload is an attractive concept and the successful precedents of the recent past set the stage for broader applications in the future. Antibody-drug conjugates may currently hold an...

  • Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates. Kamath, Amrita; Iyer, Suhasini // Pharmaceutical Research;Nov2015, Vol. 32 Issue 11, p3470 

    Antibody drug conjugates (ADCs) are an emerging new class of targeted therapeutics for cancer that use antibodies to deliver cytotoxic drugs to cancer cells. There are two FDA approved ADCs on the market and over 30 ADCs in the clinical pipeline against a number of different cancer types. The...

  • Getting to the Core. Davis, Mindy I.; Simeonov, Anton; Lea, Wendy; Parker, Christian; Auld, Doug // Assay & Drug Development Technologies;May2014, Vol. 12 Issue 4, p197 

    The article presents abstracts on drug development topics which include three dimensional screening for the identification of copmpounds that target cells in dormant tumor spheroid regions, site-specific antibody drug conjugates, and sequence-based design of oligonucleotides to target microRNA.

  • TGF-β1 Reduces miR-29a Expression to Promote Tumorigenicity and Metastasis of Cholangiocarcinoma by Targeting HDAC4. Wang, Huiling; Li, Caixia; Jian, Zhixiang; Ou, Yingliang; Ou, Jinrui // PLoS ONE;10/6/2015, Vol. 10 Issue 10, p1 

    Transforming growth factor β1 (TGF-β1) and miRNAs play important roles in cholangiocarcinoma progression. In this study, miR-29a level was found significantly decreased in both cholangiocarcinoma tissues and tumor cell lines. TGF-β1 reduced miR-29a expression in tumor cell lines....

  • INGs are potential drug targets for cancer. Zhang, Runyun; Jin, Jianhua; Shi, Juanjuan; Hou, Yongzhong // Journal of Cancer Research & Clinical Oncology;Feb2017, Vol. 143 Issue 2, p189 

    Purpose: The inhibitor of growth (ING) family consists of ING1, ING2, ING3, ING4 and ING5, which function as the type II tumor suppressors. INGs regulate cell proliferation, senescence, apoptosis, differentiation, angiogenesis, DNA repair, metastasis, and invasion by multiple pathways. In...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics